Potential for targeted therapy in prostate cancers with ERG abnormalities

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2011,（6）
• 页码范围: 781-782
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.100

摘要

Since the recent identification of recurrent gene fusions in prostate cancer between members of the ETS family of genes and transmembrane protease,serine 2 (TM PRSS2),1,2 a tremendous amount of interest has developed in the pathways through which these fusions contribute to prostatic carcinogenesis,as well as their diagnostic utility,prognostic value and therapeutic implications.